EHA RUBY oral presentation on Saturday, June 15 at 11:30 a.m. CEST/5:30 a.m. EDT "I am encouraged by these results from the RUBY trial, demonstrating this investigational gene editing medicine has been well-tolerated and shows promising efficacy for people living with sickle cell disease. Treatment with reni-cel showed a favorable safety profile and promising preliminary efficacy, supporting further investigation as a differentiated gene-edited medicine for patients with SCD. We look forward to continuing t ...

All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion In the EdiTHAL trial to date, reni-cel was well-tolerated and continues to demonstrate a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant by all patients (N=7). Following treatment with reni-cel, all EdiTHAL patients had early and robust increase of total ...

Editas Medicine, Inc. (NASDAQ:EDIT) RBC Capital Markets Global Healthcare Conference Call May 15, 2024 2:05 PM ET Company Participants Gilmore O’Neill - Chief Executive Officer Conference Call Participants Luca Issi - RBC Capital Markets Luca Issi Thanks, everybody. Luca Issi, senior biotech analyst here at RBC Capital Markets. Today is our great privilege to have Editas for us with us with a fireside chat. Representing the company, we have Gilmore O’Neill, Chief Executive Officer. Gilmore thanks so much fo ...

Editas Medicine, Inc. (NASDAQ:EDIT) RBC Capital Markets Global Healthcare Conference Call May 15, 2024 2:05 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Conference Call Participants Luca Issi - RBC Capital Markets Luca Issi Thanks, everybody. Luca Issi, senior biotech analyst here at RBC Capital Markets. Today is our great privilege to have Editas for us with us with a fireside chat. Representing the company, we have Gilmore O'Neill, Chief Executive Officer. Gilmore thanks so much fo ...

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream. Clinical data from pati ...

Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications Data to support development of the Company's in vivo gene editing medicines pipeline   CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced the presentation of preclinical data demonstrating several in vivo capabilities towards developing transformative in vivo gene editing medicines. The C ...

Editas Medicine, Inc. (EDIT) incurred a loss of 76 cents per share in the first quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 63 cents. The company had reported a loss of 71 cents per share in the year-ago quarter.Collaboration and other research and development (R&D) revenues, which comprise the company’s top line, were $1.1 million in the first quarter, down from $9.8 million reported in the year-ago quarter. The reported figure missed the Zacks Consensus Estimate of $12 million. T ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________ FORM 10-Q _______________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR For the transition period from ____________ to ________ Commission File Number 001-37687 __________________ ...

Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - CEO Baisong Mei - CMO Erick Lucera - CFO Linda Burkly - CSO Caren Deardorf - Chief Commercial and Strategy Officer Conference Call Participants Samantha Semenkow - Citi Joon Lee - Truist Securities Mary Kate Davis - Bank of America Jack Allen - Baird Gena Wang - Barclays Brian Cheng - JPMorgan Eric Schmidt - Cantor Fitzgerald Jay ...

Editas Medicine (EDIT) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -20.63%. A quarter ago, it was expected that this genome editing company would post a loss of $0.52 per share when it actually produced a loss of $0.23, delivering a surprise of 55.77%.Over the last four quarters, the comp ...